The Board of Directors at their meeting held on May 09, 2025, approved the recommendation of Final Dividend subject to the approval of shareholders at the ensuing AGM.
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's Board has recommended a final dividend of Rs 25 per equity share (on face value of Rs 5) for FY25, unchanged from the previous year's Rs 25 per share. Dividend is subject to shareholder approval at the 77th AGM scheduled for July 31, 2025, with book closure from July 24 to July 31, 2025. For FY25, the company reported revenue from operations of Rs 3,562.7 million (up about 6% from Rs 3,350.7 million in FY24) and net profit of Rs 1,009 million (up about 18% from Rs 851.9 million), translating to EPS of Rs 40.87 versus Rs 34.50 last year. The Board also approved the re-appointment of Mr. Sanker Parameswaran as Independent Director for a second 5-year term and appointed M K Saraf & Associates LLP as Secretarial Auditors for 5 years.
The unchanged Rs 25 dividend signals a stable payout policy rather than growth, while the strong ~18% rise in net profit and EPS is a positive operational signal for shareholders. With healthy cash balances and no debt, the stock remains a steady dividend-paying pharma name, though the flat dividend may limit near-term yield-driven upside.